Interleukin-17, produced by lymphocytes, promotes tumor growth and angiogenesis in a mouse model of breast cancer

Molecular Medicine Reports

Volumn 6, Issue 5, 2012, Pages 1099-1102

  Du, Jiu Wei ^a   Xu, Ke Yi ^a   Fang, Li Yi ^a   Qi, Xin Lan ^a  

^a ANHUI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Angiogenesis; Breast cancer; Interleukin 17; Mouse model

Indexed keywords

CD3 ANTIBODY; INTERLEUKIN 17; MONOCLONAL ANTIBODY CD28; PHORBOL 13 ACETATE 12 MYRISTATE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INFILTRATION; CELL COUNT; CELL PROLIFERATION; FEMALE; LYMPHOCYTE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, CD34; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; INTERLEUKIN-17; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; PHORBOL ESTERS; RECOMBINANT PROTEINS;

MURINAE; MUS;

EID: 84866447222     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1036     Document Type: Article

References (17)

1. Wright SE: Immunotherapy of breast cancer. Expert Opin Biol Ther 12: 479-490, 2012.
2. World Health Organization. http://www.who.int/cancer/detection/ breastcancer/en/index1.html. Accessed April 2012.
3. Peng J, Sengupta S and Jordan VC: Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anticancer Agents Med Chem 9: 481-499, 2009.
4. Howard JH and Bland KI: Current management and treatment strategies for breast cancer. Curr Opin Obstet Gynecol 24: 44-48, 2012.
5. Novitskiy SV, Pickup MW, Gorska AE, et al: TGF-β Receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. Cancer Discov 1: 430-441, 2011.
6. Afzali B, Lombardi G, Lechler RI and Lord GM: The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 148: 32-46, 2007. (Pubitemid 46365005)
7. Yang L, Qi Y, Hu J, Tang L, Zhao S and Shan B: Expression of Th17 cells in breast cancer tissue and its association with clinical parameters. Cell Biochem Biophys 62: 153-159, 2012.
8. Pappu R, Ramirez-Carrozzi V and Sambandam A: The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology 134: 8-16, 2011.
9. Zhu X, Mulcahy LA, Mohammed RA, et al: IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 10: R95, 2008.
10. Weidner N: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36: 169-180, 1995.
11. Harrington LE, Haaon RD, Mangan PR, Turner H, Murphy TL, Murphy KM and Weaver CT: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123-1132, 2005. (Pubitemid 41541790)
12. Fossiez F, Banchereau J, Murray R, Van Kooten C, Garrone P and Lebecque S: Interleukin-17. Int Rev Immunol 16: 541-551, 1998. (Pubitemid 28286184)
13. Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma L, Xue X, Wei G, Liu X and Fang G: The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 374: 533-537, 2008.
14. Le Gouvello S, Bastuji-Garin S, Aloulou N, et a1: High prevalence of Foxp3 and IL-17 in MMR-proficient colorectal carcinomas. Gut 57: 772-779, 2008.
15. Numasaki M, Watanabe M, Suzuki T, et a1: IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175: 6177-6189, 2005.
16. Shime H, Yabu M, Akazawa T, Kodama K, Matsumoto M, Seya T and Inoue N: Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J Immunol 180: 7175-7183, 2008.
17. Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, Chang A and Zou W: Cutting ease: Thl7 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178: 6730-6733, 2007. (Pubitemid 46847396)